Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE - Free Report) - Equities research analysts at Wedbush issued their FY2029 earnings per share estimates for Monte Rosa Therapeutics in a research note issued on Thursday, March 20th. Wedbush analyst R. Driscoll forecasts that the company will post earnings of ($1.33) per share for the year. Wedbush currently has a "Outperform" rating and a $17.00 price objective on the stock. The consensus estimate for Monte Rosa Therapeutics' current full-year earnings is ($1.49) per share.
Monte Rosa Therapeutics (NASDAQ:GLUE - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.60. The firm had revenue of $14.00 million for the quarter, compared to analysts' expectations of $43.73 million.
A number of other research analysts also recently commented on GLUE. Lifesci Capital assumed coverage on shares of Monte Rosa Therapeutics in a research note on Wednesday, March 12th. They set an "outperform" rating and a $19.00 price objective on the stock. Wells Fargo & Company lowered their price target on Monte Rosa Therapeutics from $11.00 to $10.00 and set an "equal weight" rating for the company in a report on Friday, March 21st.
View Our Latest Stock Analysis on GLUE
Monte Rosa Therapeutics Trading Down 4.2 %
NASDAQ GLUE traded down $0.23 during mid-day trading on Monday, reaching $5.26. 642,450 shares of the company's stock traded hands, compared to its average volume of 940,584. The company has a fifty day simple moving average of $6.17 and a 200-day simple moving average of $6.77. Monte Rosa Therapeutics has a 1-year low of $3.21 and a 1-year high of $12.40. The company has a market cap of $323.54 million, a price-to-earnings ratio of -2.87 and a beta of 1.50.
Insider Buying and Selling at Monte Rosa Therapeutics
In other news, Director Chandra P. Leo acquired 10,000 shares of the company's stock in a transaction dated Monday, March 24th. The shares were bought at an average price of $5.84 per share, with a total value of $58,400.00. Following the purchase, the director now owns 10,000 shares of the company's stock, valued at approximately $58,400. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.50% of the stock is owned by company insiders.
Institutional Investors Weigh In On Monte Rosa Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the business. Tower Research Capital LLC TRC boosted its holdings in Monte Rosa Therapeutics by 192.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 5,443 shares of the company's stock worth $38,000 after buying an additional 3,584 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Monte Rosa Therapeutics by 10,665.5% in the 4th quarter. GAMMA Investing LLC now owns 5,921 shares of the company's stock worth $41,000 after acquiring an additional 5,866 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter worth $43,000. Virtus ETF Advisers LLC purchased a new stake in shares of Monte Rosa Therapeutics during the fourth quarter valued at $63,000. Finally, Focus Partners Wealth acquired a new position in shares of Monte Rosa Therapeutics in the 4th quarter valued at $77,000. 79.96% of the stock is owned by institutional investors and hedge funds.
Monte Rosa Therapeutics Company Profile
(
Get Free Report)
Monte Rosa Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases.
See Also
Before you consider Monte Rosa Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Monte Rosa Therapeutics wasn't on the list.
While Monte Rosa Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
